Epizyme won accelerated FDA approval Thursday for a drug developed to treat the rare cancer epithelioid sarcoma (ES).
The regulatory decision for the Epizyme (NASDAQ: EPZM) drug, tazemetostat (Tazverik), covers patients 16 or older whose ES has advanced or spread and is not eligible for surgical treatment. The drug is now the first FDA-approved treatment for this type of cancer, laying the groundwork for potential applications of the therapy in other cancers.
Cambridge, MA-based Epizyme set a $15,500 per month wholesale price for tazemetostat, before any discounts or rebates. The company aims to make the drug available within the next… Read more »
UNDERWRITERS AND PARTNERS
